This is a Phase II, sequential cohort, randomized, double-blind, placebo controlled, dose escalation trial of 3 doses of adefovir dipivoxil (30 mg, 60 mg and 120 mg/day) or placebo administered orally once daily for 12 weeks for the treatment of chronic hepatitis B virus infection. All subjects will also receive a daily escalation to the next higher dose to occur after 12 subjects have completed study drug dosing for at least 4 weeks and the independent Data Safety Monitoring Board has reviewed the safety and HBV-DNA data from these participants and determined the drug to be safe for dose escalation.
Showing the most recent 10 out of 563 publications